

Resource Summary Report

Generated by [NIF](#) on Sep 17, 2026

HCC4006

RRID:CVCL_1269

Type: Cell Line

Proper Citation

RRID:CVCL_1269

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1269

Proper Citation: RRID:CVCL_1269

Description: Cell line HCC4006 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung adenocarcinoma

Defining Citation: [PMID:16187286](#), [PMID:20679594](#), [PMID:22460905](#), [PMID:22961666](#), [PMID:23733853](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26361996](#), [PMID:26589293](#), [PMID:29681454](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:39061985](#)

Comments: Miscellaneous: Direct author submission of STR profile from Girard, Luc & Gazdar, Adi F., Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: EGFR genetic alteration cell panel (ATCC TCP-1027)., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HCC4006

Synonyms: HCC-4006, Hamon Cancer Center 4006

Cross References: BTO:BTO_0004081, CLO:CLO_0003657, EFO:EFO_0003132, AddexBio:C0016012/4917, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ATCC:CRL-2871, BioSample:SAMN03471807, BioSample:SAMN03473288, BioSample:SAMN10988526, cancercellines:CVCL_1269, Cell_Model_Passport:SIDM01596, ChEMBL-Cells:ChEMBL4523544, ChEMBL-Targets:ChEMBL4523575, CLS:305785, Cosmic:903602, Cosmic:1028938,

Cosmic:1128250, Cosmic:1146936, Cosmic:1802302, Cosmic:2015233, DepMap:ACH-000066, EGA:EGAS00001000610, EGA:EGAS00001002554, GEO:GSM63351, GEO:GSM108873, GEO:GSM108874, GEO:GSM253408, GEO:GSM434286, GEO:GSM794399, GEO:GSM817126, GEO:GSM844552, GEO:GSM887055, GEO:GSM888125, IARC_TP53:30035, IGRhCellID:HCC4006GEO, LiGeA:CCLE_139, PharmacDB:HCC4006_502_2019, PRIDE:PXD002556, Progenetix:CVCL_1269, PubChem_Cell_line:CVCL_1269, Wikidata:Q54881724

ID: CVCL_1269

Record Creation Time: 20220427T220319+0000

Record Last Update: 20260913T003953+0000

Ratings and Alerts

No rating or validation information has been found for HCC4006.

No alerts have been found for HCC4006.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 149 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Stern YE, et al. (2026) Targeting CDK12/13 Drives Mitotic Arrest to Overcome Resistance to KRASG12C Inhibitors. Cancer research, 86(2), 485.

Lobb RJ, et al. (2026) Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature. Cell reports. Medicine, 7(4), 102694.

Plowman T, et al. (2025) Primate retroelement exonization and sexually dimorphic IL13RA1 transcription tune type 2 immune responses. Science immunology, 10(109), eadr1105.

Park J, et al. (2025) MYC plus class IIa HDAC inhibition drives mitochondrial dysfunction in non-small cell lung cancer. Cell reports, 44(6), 115722.

Baro M, et al. (2025) Redundancy of the OST catalytic subunit facilitates therapeutic targeting of N-glycosylation. Cell chemical biology, 32(6), 839.

Kahlhofer J, et al. (2025) TXNIP mediates LAT1/SLC7A5 endocytosis to limit amino acid uptake in cells entering quiescence. The EMBO journal, 44(23), 7119.

Meng X, et al. (2025) SERPINB3 enhances NPM1 sumoylation via inhibiting SENP3's activity and promotes lung tumorigenesis. *Cell death & disease*, 17(1), 133.

Loong J, et al. (2025) Retroelement co-option disrupts the cancer transcriptional programme. *Genome medicine*, 17(1), 48.

Yang Y, et al. (2025) The Activity of EGFR CAR NK and CAR T Cells against EGFR Inhibitor-Resistant NSCLC and Drug-Tolerant Persister Cells. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(22), 4745.

Alsaed B, et al. (2025) Intratumor heterogeneity of EGFR expression mediates targeted therapy resistance and formation of drug tolerant microenvironment. *Nature communications*, 16(1), 28.

Pulice JL, et al. (2025) Amplified dosage of the NKX2-1 lineage transcription factor controls its oncogenic role in lung adenocarcinoma. *Molecular cell*, 85(7), 1311.

Baldacci S, et al. (2025) Eradicating Drug Tolerant Persister Cells in EGFR-Mutated Non-Small Cell Lung Cancer by Targeting TROP2 with CAR-T cellular therapy. *Cancer discovery*.

Thomas JD, et al. (2024) Development of a Novel DNA Mono-alkylator Platform for Antibody-Drug Conjugates. *Molecular cancer therapeutics*, 23(4), 541.

Sadeghi M, et al. (2024) Biased signaling by mutant EGFR underlies dependence on PKC?? in lung adenocarcinoma. *Cell reports*, 43(12), 115026.

Pelos G, et al. (2024) Fast proliferating and slowly migrating non-small cell lung cancer cells are vulnerable to decitabine and retinoic acid combinatorial treatment. *International journal of cancer*, 154(6), 1029.

Ishibashi K, et al. (2024) Astrocyte-induced mGluR1 activates human lung cancer brain metastasis via glutamate-dependent stabilization of EGFR. *Developmental cell*, 59(5), 579.

Nagoya A, et al. (2023) CKAP4 is a potential exosomal biomarker and therapeutic target for lung cancer. *Translational lung cancer research*, 12(3), 408.

Qiao Y, et al. (2023) Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection. *PloS one*, 18(2), e0281281.

Garana BB, et al. (2023) Drug mechanism enrichment analysis improves prioritization of therapeutics for repurposing. *BMC bioinformatics*, 24(1), 215.

Aldonza MBD, et al. (2023) Multi-targeted therapy resistance via drug-induced secretome fucosylation. *eLife*, 12.